Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 110

Results For "first"

3340 News Found

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
News | August 02, 2025

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter


Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
News | August 01, 2025

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY


Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
People | July 31, 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion


Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
News | July 31, 2025

Imfinzi granted Priority Review and Breakthrough Therapy Designation in US

For patients with resectable early-stage gastric and gastroesophageal junction cancers


Torrent Pharmaceuticals appoints Aman Mehta as MD
People | July 29, 2025

Torrent Pharmaceuticals appoints Aman Mehta as MD

Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York


GSK forges $12 billion alliance with Hengrui Pharma
News | July 28, 2025

GSK forges $12 billion alliance with Hengrui Pharma

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology


Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
News | July 24, 2025

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore


Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
News | July 24, 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio


Lonza reports 19% growth in sales in H1
News | July 23, 2025

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook